Patent Baristas

Patent Baristas is hosting an Autumnal Edition of Blawg Review on Monday. Blawg Review is the blog carnival for everyone interested in law with topics discussed by lawyers, law students and law professors. Each weekly issue of Blawg Review is made up of article submissions selected from the best recent law blog posts. Blawg Review […]

While biotechnology accounts for only 1 percent of the overall healthcare costs, the overall cost of biotechnology is growing faster than the economy along an unsustainable trajectory. Biotech drug sales are expected to top $60 billion by 2010. Still, the cost of biotechnology has to be compared with the cost of the disease in terms […]

Assets acquired in today’s private equity and venture deals, mergers and acquisitions, strategic alliances and joint ventures are increasingly intellectual property assets such as patents, copyrights and Internet domain names. Because of the value of these assets, intellectual property due diligence has become an important part of the legal work required for these transactions. Such […]

Legislators are stepping up the pressure in the long running saga of getting generic versions of biotech drugs to market. The FDA approves generic versions of pharmaceutical (small molecule) drugs once the patents for brand-name products expire. But complex biotech drugs do not have such an approval process. Representative Henry Waxman and Senator Orrin Hatch […]

If you’ve ever worked with university inventors, you know that the pressure to publish is intense. Sometimes, that drive to publish comes back to bite you. An invention can only be protected by patent if it is novel (that is, no prior publication of the invention has been made by the inventor or others). While […]

I’ve said it before and I’ll say it again, if you do research you must keep meticulous notes of the inventive process. Laboratory notebooks often play an important role during the patent prosecution process and even after a patent has issued. A properly kept notebook is invaluable in cases in which another party claims a […]

AstraZeneca filed a request for an advisory opinion from the FDA pursuant to 21 C.F.R, § 10.85, asking whether patents directed to drug delivery systems, such as inhalation devices, that do not recite the approved active ingredient or formulation should be listed in the “Approved Drug Products With Therapeutic Equivalence Evaluations” (“Orange Book“). 21 C.F.R. […]

Ariad Denied Declaratory Judgment Ariad Pharmaceuticals announced that the United States District Court for the District of Delaware denied their motion to dismiss the lawsuit filed by Amgen relating to their products Enbrel(R) and Kineret(R). In the lawsuit, Amgen is seeking a declaratory judgment that these products do not infringe U.S. Patent No. 6,410,516, covering […]